| EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer (NCT07649655) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2026-07-01 |
| A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors. (NCT07607054) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2026-05-26 |
| A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma (NCT07432022) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2026-03-01 |
| Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients (NCT07314294) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2025-12-18 |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer (NCT05498389) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2023-06-01 |
| A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. (NCT05263180) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2022-07-25 |
| EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers (NCT05176665) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-10-21 |
| A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma (NCT04735575) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-05-20 |
| A Study of EMB-02 in Participants With Advanced Solid Tumors (NCT04618393) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-03-11 |
| A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (NCT03797391) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2018-12-13 |